{"The": [0, 92, 133], "prognosis": [1], "of": [2, 15, 72, 118, 137, 153, 203, 213, 253, 261, 270, 330], "patients": [3, 32, 85, 120, 205, 263, 277], "with": [4, 33, 80, 86, 318, 326], "early": [5], "relapsed": [6, 43], "or": [7, 41, 65, 69, 188, 256, 283, 294, 307], "refractory": [8, 39], "large": [9, 34], "B-cell": [10, 35], "lymphoma": [11, 36], "after": [12, 49], "the": [13, 90, 156, 164, 171, 175, 204, 207, 216, 232, 242, 248, 262, 327], "receipt": [14], "first-line": [16, 50], "chemoimmunotherapy": [17, 51], "is": [18], "poor.In": [19], "this": [20], "international,": [21], "phase": [22], "3": [23, 255, 282, 293], "trial,": [24], "we": [25], "randomly": [26, 122], "assigned,": [27], "in": [28, 84, 163, 170, 201, 206, 211, 215, 223, 241, 247, 259, 268, 289, 298, 321], "a": [29, 87, 150, 220], "1:1": [30], "ratio,": [31], "that": [37, 141], "was": [38, 96, 114, 144, 160, 179, 239], "to": [40, 52, 89, 100, 124, 129, 146, 195, 303, 313], "had": [42], "no": [44], "more": [45], "than": [46], "12": [47], "months": [48, 162, 169], "receive": [53, 125, 130], "axicabtagene": [54], "ciloleucel": [55], "(axi-cel,": [56], "an": [57, 229], "autologous": [58, 81], "anti-CD19": [59], "chimeric": [60], "antigen": [61], "receptor": [62], "T-cell": [63], "therapy)": [64], "standard": [66, 131, 147, 274, 319], "care": [67], "(two": [68], "three": [70], "cycles": [71], "investigator-selected,": [73], "protocol-defined": [74], "chemoimmunotherapy,": [75], "followed": [76], "by": [77, 335], "high-dose": [78], "chemotherapy": [79], "stem-cell": [82], "transplantation": [83], "response": [88, 109, 199, 222], "chemoimmunotherapy).": [91], "primary": [93, 134], "end": [94, 106], "point": [95], "event-free": [97, 138, 158, 177, 322], "survival": [98, 139, 159, 178, 235, 323], "according": [99], "blinded": [101], "central": [102], "review.": [103], "Key": [104], "secondary": [105], "points": [107], "were": [108, 121], "and": [110, 127, 167, 174, 181, 210, 225, 245, 267, 291, 324], "overall": [111, 234], "survival.": [112], "Safety": [113], "also": [115], "assessed.A": [116], "total": [117], "180": [119], "assigned": [123], "axi-cel": [126, 142, 165, 208, 243, 266], "179": [128], "care.": [132, 148, 275], "end-point": [135], "analysis": [136], "showed": [140], "therapy": [143, 311], "superior": [145], "At": [149], "median": [151, 157], "follow-up": [152], "24.9": [154], "months,": [155], "8.3": [161], "group": [166, 209, 218, 244], "2.0": [168], "standard-care": [172, 217, 249], "group,": [173], "24-month": [176], "41%": [180], "16%,": [182], "respectively": [183], "(hazard": [184], "ratio": [185], "for": [186], "event": [187], "death,": [189], "0.40;": [190], "95%": [191], "confidence": [192], "interval,": [193], "0.31": [194], "0.51;": [196], "P<0.001).": [197], "A": [198], "occurred": [200, 258, 288], "83%": [202, 269], "50%": [212], "those": [214, 271], "(with": [219], "complete": [221], "65%": [224], "32%,": [226], "respectively).": [227], "In": [228], "interim": [230], "analysis,": [231], "estimated": [233], "at": [236], "2": [237], "years": [238], "61%": [240], "52%": [246], "group.": [250], "Adverse": [251], "events": [252, 297, 309], "grade": [254, 281, 292], "higher": [257, 284, 295], "91%": [260], "who": [264, 272, 278], "received": [265, 273, 279], "Among": [276], "axi-cel,": [280], "cytokine": [285, 304], "release": [286, 305], "syndrome": [287, 306], "6%": [290], "neurologic": [296, 308], "21%.": [299], "No": [300], "deaths": [301], "related": [302], "occurred.Axi-cel": [310], "led": [312], "significant": [314], "improvements,": [315], "as": [316], "compared": [317], "care,": [320], "response,": [325], "expected": [328], "level": [329], "high-grade": [331], "toxic": [332], "effects.": [333], "(Funded": [334], "Kite;": [336], "ZUMA-7": [337], "ClinicalTrials.gov": [338], "number,": [339], "NCT03391466.).": [340]}